Details for Patent: 8,143,212
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 8,143,212 protect, and when does it expire?
Patent 8,143,212 protects DALVANCE and is included in one NDA.
This patent has fifty-eight patent family members in twenty countries.
Summary for Patent: 8,143,212
Title: | Dalbavancin compositions for treatment of bacterial infections |
Abstract: | The invention provides methods and compositions for treatment of bacterial infections. The composition may be a combination of factors, which include A.sub.0, A.sub.1, B.sub.1, B.sub.2, C.sub.0, C.sub.1, isoB.sub.0, and MAG, in the presence of low level solvent. Methods of the invention include administration of dalbavancin formulations for treatment of a bacterial infection, in particular a Gram-positive bacterial infection of skin and soft tissue. Dosing regimens include multiple dose administration of dalbavancin, which often remains at therapeutic levels in the bloodstream for at least one week, providing prolonged therapeutic action against a bacterial infection. Dosing regimens for renal patients are also included. |
Inventor(s): | Stogniew; Martin (Blue Bell, PA), Colombo; Luigi (Malnate, IT), Ciabatti; Romeo (Novate Milanese, IT) |
Assignee: | Vicuron Pharmaceuticals Inc. (Morristown, NJ) |
Application Number: | 12/476,785 |
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 8,143,212
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Allergan | DALVANCE | dalbavancin hydrochloride | POWDER;INTRAVENOUS | 021883-001 | May 23, 2014 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | TREATMENT OF BACTERIAL INFECTIONS USING A TWO-DOSE REGIMEN OF DALBAVANCIN. | See Plans and Pricing | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,143,212
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2003294262 | See Plans and Pricing | |||
Australia | 2003298662 | See Plans and Pricing | |||
Australia | 2003299561 | See Plans and Pricing | |||
Australia | 2005325261 | See Plans and Pricing | |||
Australia | 2011200423 | See Plans and Pricing | |||
Brazil | PI0510269 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |